Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business UpdatesPRNewsWire • 11/03/22
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentSeeking Alpha • 09/14/22
Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business UpdatesPRNewsWire • 09/12/22
Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022PRNewsWire • 09/10/22
Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022PRNewsWire • 09/06/22
Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022PRNewsWire • 08/29/22
Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business UpdatesPRNewsWire • 08/04/22
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/28/22
Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/06/22
Cardiff Oncology Reports First Quarter 2022 Results and Provides Business UpdatesPRNewsWire • 05/05/22
Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual MeetingPRNewsWire • 04/08/22
Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer ModelsPRNewsWire • 04/08/22
Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLCPRNewsWire • 03/22/22
Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual MeetingPRNewsWire • 03/08/22